Newspaper article The Journal (Newcastle, England)
Pharmaceutical Industry Is Manufacturing Growth
THE North East of England has much to be proud about regarding the pharmaceutical industry located in the region, few places in the world can say that they have the full range of pharmaceutical value chain based there, yet we can.
The region is also the only net exporting region in the UK economy and this is largely down to the industries based on or around chemistry. Up to pounds 3bn of the annual pounds 12bn of exports come from the region's pharmaceutical Industry. More than 35% of the UK's GDP in pharmaceuticals continues to be manufactured here.
There are several of the world's leading pharmaceutical companies based in the region as well as home-grown companies such as Specials Labs, which operates from a base in Prudhoe, while the success of Cramlington-based Aesica Pharmaceuticals has been outstanding by any yardstick.
Following its most successful year to date in 2010, Aesica Pharmaceuticals has doubled in size and has successfully expanded into new markets. The company's vision is to become the world's leading supplier of Active Pharmaceutical Ingredients (APIs) and Formulated Products, and recent developments we hope will enable Aesica to rapidly achieve this.
It is already one of the fastest-growing UK companies, increasing its turnover by 300% in the last five years. In doing so it was ranked 3rd in Deloitte's 2011 Buyout Track 100 as published in The Sunday Times.
In 2010 it acquired Nottingham-based R5 Pharmaceuticals and three European sites from leading Belgian pharmaceutical firm, UCB. In addition, new business development managers were recruited for San Diego and New York in preparation for further expansion across America.
The company now has 1,300 staff compared to the 150 or so that started off the company when it was spun out of BASF.
There has been growth and development at GlaxoSmithKline, MSD, sanofi-aventis, Piramel Healthcare and Shasun Pharma Solutions. Many have reported increased productivity and investment in their manufacturing facilities, particularly into biopharmaceutical capabilities. In some cases, products have been relocating from elsewhere in the world back to the NE factories. …